SCHEMBL3035931

SCHEMBL3035931

CCOC(=O)c1ccc(N2CCCN(c3ccc(Oc4ccc(NC(=O)c5ccc(C(F)(F)F)cc5)cn4)c(C)c3)C2=O)cc1

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 2/20 0.47
L3MBTL1 Q9Y468 2/20 0.44
GAA P10253 2/20 0.44
NPC1 O15118 1/20 0.44
TNF P01375 1/20 0.44
NOD1 Q9Y239 1/20 0.44
HTR2A P28223 3/20 0.43
HTR2C P28335 3/20 0.43
HTR2B P41595 2/20 0.43
MAPT P10636 4/20 0.43
MAPK1 P28482 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
MCHR1 Q99705 1/20 0.41
KIT P10721 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
POLB P06746 1/20 0.40
BTK Q06187 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8919642 0.83 HDAC1 (0.43) RAB9AL3MBTL1GAANPC1TNF
SCHEMBL8919564 0.81 HDAC1 (0.41) RAB9AL3MBTL1GAANPC1TNF
SCHEMBL3135108 0.79 MAPT (0.46) RAB9AL3MBTL1GAANPC1MAPT
SCHEMBL3134678 0.78 HDAC1 (0.46) RAB9AL3MBTL1GAANPC1TNF
SCHEMBL8922892 0.76 LMNA (0.41) RAB9AGAANPC1MAPTMAPK1
SCHEMBL1290899 0.76 RAB9A (0.60) RAB9AL3MBTL1GAANPC1TNF
SCHEMBL31305897 0.76 RAB9A (0.60) RAB9AL3MBTL1GAANPC1TNF
Hydrochloric Acid SCHEMBL1290649 0.75 RAB9A (0.59) RAB9AL3MBTL1GAANPC1TNF
Hydrochloric Acid SCHEMBL31305933 0.75 RAB9A (0.59) RAB9AL3MBTL1GAANPC1TNF
SCHEMBL3067963 0.73 RAB9A (0.49) RAB9AL3MBTL1GAANPC1TNF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1957073-B1 MEDICINAL DRUG OTSUKA PHARMA CO LTD (JP) 2014-04-23 EP claimed
EP-2612858-A1 STAT3/5 activation inhibitor OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-07-10 EP claimed
US-20120238750-A1 AROMATIC COMPOUND OTSUKA PHARMACEUTICAL CO., LTD. 2012-09-20 US claimed
US-20100210661-A1 STAT3/5 ACTIVATION INHIBITOR OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2010-08-19 US claimed
US-20100004438-A1 DIARYLETHER DERIVATIVES AS ANTITUMOR AGENTS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2010-01-07 US claimed
EP-2089373-A1 STAT3/5 ACTIVATION INHIBITOR OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2009-08-19 EP claimed
EP-1957073-A2 MEDICINAL DRUG OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2008-08-20 EP claimed
WO-2008044667-A1 STAT3/5 ACTIVATION INHIBITOR OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2008-04-17 WO claimed
US-20070270422-A1 Aromatic Compounds OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-11-22 US claimed
WO-2007066784-A2 DIARYLETHER DERIVATIVES AS ANTITUMOR AGENTS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-06-14 WO claimed
EP-1773797-A2 AROMATIC COMPOUNDS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-04-18 EP claimed
WO-2006014012-A2 AROMATIC COMPOUNDS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-02-09 WO claimed
CN-101522657-B STAT3/5 activation inhibitor OTSUKA PHARMACEUTICAL CO.,LTD. (JP) 2014-10-15 CN disclosed
EP-1957073-B1 MEDICINAL DRUG OTSUKA PHARMA CO LTD (JP) 2014-04-23 EP disclosed
EP-2612858-A1 STAT3/5 activation inhibitor OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-07-10 EP disclosed
CN-1993339-B Aromatic compound OTSUKA PHARMA CO LTD 2013-05-22 CN disclosed
WO-2007066784-A2 DIARYLETHER DERIVATIVES AS ANTITUMOR AGENTS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-06-14 WO disclosed
WO-2007066784-A2 DIARYLETHER DERIVATIVES AS ANTITUMOR AGENTS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-06-14 WO disclosed
EP-1773797-A2 AROMATIC COMPOUNDS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-04-18 EP disclosed
WO-2006014012-A2 AROMATIC COMPOUNDS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-02-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120238750-A1 AROMATIC COMPOUND CBR1, CBR3, CYP1A1 RAB9A 2782/4885L3MBTL1 502/4885GAA 4225/4885
US-20100210661-A1 STAT3/5 ACTIVATION INHIBITOR STAT3, JAK2, STAT1 RAB9A 3779/4885L3MBTL1 2478/4885GAA 3958/4885
US-20100004438-A1 DIARYLETHER DERIVATIVES AS ANTITUMOR AGENTS ROS1, CBR1, CBR3 RAB9A 2323/4885L3MBTL1 533/4885GAA 3133/4885
US-20070270422-A1 Aromatic Compounds COL1A1, COL2A1, COL14A1 RAB9A 3123/4885L3MBTL1 1465/4885GAA 3249/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.